Literature DB >> 26494962

Endocrine causes of nonalcoholic fatty liver disease.

Laura Marino1, François R Jornayvaz1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the industrialized world. The prevalence of NAFLD is increasing, becoming a substantial public health burden. NAFLD includes a broad spectrum of disorders, from simple conditions such as steatosis to severe manifestations such as fibrosis and cirrhosis. The relationship of NAFLD with metabolic alterations such as type 2 diabetes is well described and related to insulin resistance, with NAFLD being recognized as the hepatic manifestation of metabolic syndrome. However, NAFLD may also coincide with endocrine diseases such as polycystic ovary syndrome, hypothyroidism, growth hormone deficiency or hypercortisolism. It is therefore essential to remember, when discovering altered liver enzymes or hepatic steatosis on radiological exams, that endocrine diseases can cause NAFLD. Indeed, the overall prognosis of NAFLD may be modified by treatment of the underlying endocrine pathology. In this review, we will discuss endocrine diseases that can cause NALFD. Underlying pathophysiological mechanisms will be presented and specific treatments will be reviewed.

Entities:  

Keywords:  Endocrine diseases; Insulin resistance; Nonalcoholic fatty liver disease; Obesity; Type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26494962      PMCID: PMC4607905          DOI: 10.3748/wjg.v21.i39.11053

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  294 in total

1.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

Review 2.  Adiponectin as a routine clinical biomarker.

Authors:  Ken Kishida; Tohru Funahashi; Iichiro Shimomura
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-08-20       Impact factor: 4.690

3.  Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese.

Authors:  Mian Li; Yu Xu; Min Xu; Lingying Ma; Tiange Wang; Yu Liu; Meng Dai; Yuhong Chen; Jieli Lu; Jianmin Liu; Yufang Bi; Guang Ning
Journal:  J Clin Endocrinol Metab       Date:  2012-03-30       Impact factor: 5.958

4.  Preliminary data on the relationship between circulating levels of Sirtuin 4, anthropometric and metabolic parameters in obese subjects according to growth hormone/insulin-like growth factor-1 status.

Authors:  Silvia Savastano; Carolina Di Somma; Annamaria Colao; Luigi Barrea; Francesco Orio; Carmine Finelli; Fabrizio Pasanisi; Franco Contaldo; Giovanni Tarantino
Journal:  Growth Horm IGF Res       Date:  2014-10-28       Impact factor: 2.372

5.  Association between bone mineral density and metabolic syndrome in pre- and postmenopausal women.

Authors:  Yun Kyung Jeon; Jeong Gyu Lee; Sang Soo Kim; Bo Hyun Kim; Seong-Jang Kim; Yong Ki Kim; In Joo Kim
Journal:  Endocr J       Date:  2011       Impact factor: 2.349

Review 6.  A concise review of non-alcoholic fatty liver disease.

Authors:  Nwe Ni Than; Philip N Newsome
Journal:  Atherosclerosis       Date:  2015-01-13       Impact factor: 5.162

Review 7.  Impact of oestrogens on the progression of liver disease.

Authors:  Ichiro Shimizu
Journal:  Liver Int       Date:  2003-02       Impact factor: 5.828

8.  Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial.

Authors:  Manal F Abdelmalek; Schuyler O Sanderson; Paul Angulo; Consuelo Soldevila-Pico; Chen Liu; Joy Peter; Jill Keach; Matt Cave; Theresa Chen; Craig J McClain; Keith D Lindor
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

Review 9.  Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review.

Authors:  Ahad Eshraghian; Alireza Hamidian Jahromi
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

10.  Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.

Authors:  Eugen Florin Georgescu; Reanina Ionescu; Mihaela Niculescu; Laurentiu Mogoanta; Liliana Vancica
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

View more
  22 in total

Review 1.  Ovarian hormones and obesity.

Authors:  Brigitte Leeners; Nori Geary; Philippe N Tobler; Lori Asarian
Journal:  Hum Reprod Update       Date:  2017-05-01       Impact factor: 15.610

2.  Computed tomographic evaluation of the thymus-does obesity affect thymic fatty involution in a healthy young adult population?

Authors:  Kate A Harrington; David S Kennedy; Bobby Tang; Conor Hickie; Emma Phelan; William Torreggiani; Darragh Halpenny
Journal:  Br J Radiol       Date:  2018-03-07       Impact factor: 3.039

3.  Growth hormone ameliorates hepatopulmonary syndrome and nonalcoholic steatohepatitis secondary to hypopituitarism in a child: A case report.

Authors:  Xiao-Yuan Zhang; Ke Yuan; Yan-Lan Fang; Chun-Lin Wang
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

4.  Papio spp. Colon microbiome and its link to obesity in pregnancy.

Authors:  XuanJi Li; Christopher Rensing; William L Taylor; Caitlin Costelle; Asker Daniel Brejnrod; Robert J Ferry; Paul B Higgins; Franco Folli; Kameswara Rao Kottapalli; Gene B Hubbard; Edward J Dick; Shibu Yooseph; Karen E Nelson; Natalia Schlabritz-Loutsevitch
Journal:  J Med Primatol       Date:  2018-07-24       Impact factor: 0.667

Review 5.  Nonalcoholic fatty liver disease as a multi-systemic disease.

Authors:  Hakan Fotbolcu; Elçin Zorlu
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

Review 6.  Metabolic aspects of adult patients with nonalcoholic fatty liver disease.

Authors:  Ludovico Abenavoli; Natasa Milic; Laura Di Renzo; Tomislav Preveden; Milica Medić-Stojanoska; Antonino De Lorenzo
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

7.  Plant-derived oleanolic acid ameliorates markers associated with non-alcoholic fatty liver disease in a diet-induced pre-diabetes rat model.

Authors:  Mlindeli Gamede; Lindokuhle Mabuza; Phikelelani Ngubane; Andile Khathi
Journal:  Diabetes Metab Syndr Obes       Date:  2019-10-01       Impact factor: 3.168

8.  Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism Among Chinese Population.

Authors:  Yi Chen; Xueyang Chen; Qiang Chen; Chaohui Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-22       Impact factor: 5.555

9.  Sex Difference in the Association between Serum Homocysteine Level and Non-Alcoholic Fatty Liver Disease.

Authors:  Bo-Youn Won; Kyung-Chae Park; Soo-Hyun Lee; Sung-Hwan Yun; Moon-Jong Kim; Kye-Seon Park; Young-Sang Kim; Ji-Hee Haam; Hyung-Yuk Kim; Hye-Jung Kim; Ki-Hyun Park
Journal:  Korean J Fam Med       Date:  2016-07-21

10.  Nonalcoholic fatty liver disease in long-term survivors of childhood-onset craniopharyngioma.

Authors:  So Yoon Jung; Yun Jeong Lee; Hye Jin Lee; Young Ah Lee; Jin Soo Moon; Jae Sung Ko; Sei Won Yang; Choong Ho Shin
Journal:  Ann Pediatr Endocrinol Metab       Date:  2017-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.